Compare Essex Property Trust, Inc. (ESS) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs TransMedics Group Inc — how do they compare? Essex Property Trust, Inc. trades at $280.48 (market cap $18.15B), while TransMedics Group Inc trades at $86.65 (market cap $3.10B). The key difference: Essex Property Trust, Inc. is far larger — about 5.9× TransMedics Group Inc's market cap, and Essex Property Trust, Inc. pays a 3.93% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| ESS | TMDX | |
|---|---|---|
Market Cap | $18.15B | $3.10B |
Sector | Real Estate | Technology |
52-Week High | $298.33 | $150.42 |
52-Week Low | $239.61 | $61.99 |
Enterprise Value | $24.75B | $3.49B |
Dividend Yield | 3.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESS trades at $282.11, down 0.39% on the day, with a bearish technical signal from moving averages and oscillators. The company reported Q2 2026 EPS of $0.97, missing expectations, but raised full-year guidance after strong property NOI growth. Revenue reached $1.89B in 2025 with a net income margin of 35.48%, though profitability is trending lower in 2026. Recent news includes ESS being named a top GreenTech company and signing a 500 MWh energy storage agreement with Juniper Energy.
The outlook is mixed: raised guidance and institutional buying support upside, but technical weakness and earnings miss pose near-term risks. Valuation ratios like P/E of 19.9 and P/S of 9.05 are reasonable for a REIT, yet debt levels and regional market volatility require caution. Analyst consensus is a Moderate Buy with a $305.86 price target, suggesting 8.4% potential upside from current levels.
TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.
Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
